JP5793073B2 - アレルギーの治療に用いるための、主要グループ１ダニアレルゲンおよび主要グループ２ダニアレルゲンの低アレルゲン性ハイブリッドタンパク質 - Google Patents
アレルギーの治療に用いるための、主要グループ１ダニアレルゲンおよび主要グループ２ダニアレルゲンの低アレルゲン性ハイブリッドタンパク質 Download PDFInfo
- Publication number
- JP5793073B2 JP5793073B2 JP2011501318A JP2011501318A JP5793073B2 JP 5793073 B2 JP5793073 B2 JP 5793073B2 JP 2011501318 A JP2011501318 A JP 2011501318A JP 2011501318 A JP2011501318 A JP 2011501318A JP 5793073 B2 JP5793073 B2 JP 5793073B2
- Authority
- JP
- Japan
- Prior art keywords
- der
- ige
- protein
- sequence
- patients
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010020751 Hypersensitivity Diseases 0.000 title claims description 52
- 230000007815 allergy Effects 0.000 title claims description 51
- 238000011282 treatment Methods 0.000 title claims description 16
- 102000004169 proteins and genes Human genes 0.000 title description 109
- 108090000623 proteins and genes Proteins 0.000 title description 109
- 239000013566 allergen Substances 0.000 title description 65
- 230000000774 hypoallergenic effect Effects 0.000 title description 10
- 239000000203 mixture Substances 0.000 claims description 42
- 210000004027 cell Anatomy 0.000 claims description 34
- 208000026935 allergic disease Diseases 0.000 claims description 30
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 229920001184 polypeptide Polymers 0.000 claims description 11
- 239000002773 nucleotide Substances 0.000 claims description 10
- 125000003729 nucleotide group Chemical group 0.000 claims description 10
- 239000013604 expression vector Substances 0.000 claims description 9
- 239000002671 adjuvant Substances 0.000 claims description 7
- 241000588724 Escherichia coli Species 0.000 claims description 6
- 108091033319 polynucleotide Proteins 0.000 claims description 6
- 239000002157 polynucleotide Substances 0.000 claims description 6
- 102000040430 polynucleotide Human genes 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 238000007920 subcutaneous administration Methods 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 210000001236 prokaryotic cell Anatomy 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 108
- 108010061608 Dermatophagoides pteronyssinus antigen p 2 Proteins 0.000 description 75
- 208000010668 atopic eczema Diseases 0.000 description 58
- 230000000172 allergic effect Effects 0.000 description 57
- 108010061629 Dermatophagoides pteronyssinus antigen p 1 Proteins 0.000 description 54
- 241000238740 Dermatophagoides pteronyssinus Species 0.000 description 46
- 230000027455 binding Effects 0.000 description 40
- 238000000034 method Methods 0.000 description 36
- 238000012360 testing method Methods 0.000 description 36
- 239000012634 fragment Substances 0.000 description 34
- 229960004784 allergens Drugs 0.000 description 29
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 24
- 238000000746 purification Methods 0.000 description 24
- 239000000284 extract Substances 0.000 description 23
- 230000009257 reactivity Effects 0.000 description 23
- 230000005764 inhibitory process Effects 0.000 description 21
- 210000002966 serum Anatomy 0.000 description 20
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 20
- 238000009169 immunotherapy Methods 0.000 description 19
- 150000001413 amino acids Chemical group 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 238000002965 ELISA Methods 0.000 description 16
- 241000238876 Acari Species 0.000 description 15
- 210000001744 T-lymphocyte Anatomy 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 14
- 239000000428 dust Substances 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- 210000003491 skin Anatomy 0.000 description 14
- 235000001014 amino acid Nutrition 0.000 description 13
- 229940024606 amino acid Drugs 0.000 description 13
- 239000002609 medium Substances 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 12
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 12
- 239000004202 carbamide Substances 0.000 description 12
- 108020001507 fusion proteins Proteins 0.000 description 12
- 102000037865 fusion proteins Human genes 0.000 description 12
- 210000003651 basophil Anatomy 0.000 description 11
- 238000003776 cleavage reaction Methods 0.000 description 11
- 230000035755 proliferation Effects 0.000 description 11
- 230000007017 scission Effects 0.000 description 11
- 230000008961 swelling Effects 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 10
- 108091008146 restriction endonucleases Proteins 0.000 description 10
- 230000002441 reversible effect Effects 0.000 description 10
- 239000007983 Tris buffer Substances 0.000 description 9
- 230000003321 amplification Effects 0.000 description 9
- 238000003199 nucleic acid amplification method Methods 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 9
- 239000013598 vector Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 108020004635 Complementary DNA Proteins 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 238000010804 cDNA synthesis Methods 0.000 description 8
- 239000002299 complementary DNA Substances 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 230000003053 immunization Effects 0.000 description 8
- 230000006698 induction Effects 0.000 description 8
- 238000003752 polymerase chain reaction Methods 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 230000004913 activation Effects 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 230000000903 blocking effect Effects 0.000 description 7
- 238000000684 flow cytometry Methods 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 230000001603 reducing effect Effects 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 229960005486 vaccine Drugs 0.000 description 7
- 229940074608 allergen extract Drugs 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 208000006673 asthma Diseases 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229960001340 histamine Drugs 0.000 description 6
- 230000002163 immunogen Effects 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 108010061569 Dermatophagoides pteronyssinus antigen p 4 Proteins 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 238000003119 immunoblot Methods 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 229920002401 polyacrylamide Polymers 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 241000238710 Dermatophagoides Species 0.000 description 4
- 108010061573 Dermatophagoides pteronyssinus antigen p 5 Proteins 0.000 description 4
- 108010061636 Dermatophagoides pteronyssinus antigen p 6 Proteins 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 238000013019 agitation Methods 0.000 description 4
- 230000002009 allergenic effect Effects 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 238000005571 anion exchange chromatography Methods 0.000 description 4
- 230000030741 antigen processing and presentation Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 238000000586 desensitisation Methods 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 238000003127 radioimmunoassay Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 3
- 101710101820 60S ribosomal protein L10-2 Proteins 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 206010010741 Conjunctivitis Diseases 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 108010061612 Dermatophagoides pteronyssinus antigen p 3 Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 206010070834 Sensitisation Diseases 0.000 description 3
- 239000012505 Superdex™ Substances 0.000 description 3
- 208000003455 anaphylaxis Diseases 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 229940062713 mite extract Drugs 0.000 description 3
- 239000002808 molecular sieve Substances 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 102000013415 peroxidase activity proteins Human genes 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 206010039083 rhinitis Diseases 0.000 description 3
- 230000008313 sensitization Effects 0.000 description 3
- 238000010181 skin prick test Methods 0.000 description 3
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 206010002199 Anaphylactic shock Diseases 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108010005843 Cysteine Proteases Proteins 0.000 description 2
- 102000005927 Cysteine Proteases Human genes 0.000 description 2
- 102000057955 Eosinophil Cationic Human genes 0.000 description 2
- 101710191360 Eosinophil cationic protein Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 241001534493 Pteronyssus Species 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 102000005937 Tropomyosin Human genes 0.000 description 2
- 108010030743 Tropomyosin Proteins 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 150000001945 cysteines Chemical class 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 210000000245 forearm Anatomy 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 230000007233 immunological mechanism Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 231100000430 skin reaction Toxicity 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 238000010396 two-hybrid screening Methods 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 101710154545 16 kDa protein Proteins 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 1
- DGZSVBBLLGZHSF-UHFFFAOYSA-N 4,4-diethylpiperidine Chemical compound CCC1(CC)CCNCC1 DGZSVBBLLGZHSF-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- VDABVNMGKGUPEY-UHFFFAOYSA-N 6-carboxyfluorescein succinimidyl ester Chemical compound C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=C2)OC(=O)C1=CC=C2C(=O)ON1C(=O)CCC1=O VDABVNMGKGUPEY-UHFFFAOYSA-N 0.000 description 1
- 241000934067 Acarus Species 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 101710166052 Apolipophorin Proteins 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010020366 Arginine kinase Proteins 0.000 description 1
- 241000238421 Arthropoda Species 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 241000536435 Blomia <angiosperm> Species 0.000 description 1
- 241000817107 Botryocladius freemani Species 0.000 description 1
- 241000072669 Brachiosphaera tropicalis Species 0.000 description 1
- 108010009861 CCTAGG-specific type II deoxyribonucleases Proteins 0.000 description 1
- 102100025222 CD63 antigen Human genes 0.000 description 1
- 241000934016 Chortoglyphus Species 0.000 description 1
- 240000001249 Cynodon radiatus Species 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 241000238713 Dermatophagoides farinae Species 0.000 description 1
- 108010061638 Dermatophagoides pteronyssinus antigen p 7 Proteins 0.000 description 1
- 241000104238 Dermatophagoides siboney Species 0.000 description 1
- 241001533144 Dermatophagoidinae Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000011891 EIA kit Methods 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 241000238741 Euroglyphus maynei Species 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000004878 Gelsolin Human genes 0.000 description 1
- 108090001064 Gelsolin Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 241001510533 Glycyphagus Species 0.000 description 1
- 241001510515 Glycyphagus domesticus Species 0.000 description 1
- 241001084383 Gohieria Species 0.000 description 1
- 108010062347 HLA-DQ Antigens Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241001588355 Hirstia Species 0.000 description 1
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 description 1
- 208000035533 House dust allergy Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241001510164 Lepidoglyphus destructor Species 0.000 description 1
- 240000004296 Lolium perenne Species 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 102000002151 Microfilament Proteins Human genes 0.000 description 1
- 108010040897 Microfilament Proteins Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 102000040229 NPC2 family Human genes 0.000 description 1
- 108091074439 NPC2 family Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 240000007643 Phytolacca americana Species 0.000 description 1
- 101710127749 Pollen allergen Phl p 2 Proteins 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 241001533135 Pyroglyphinae Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 101100289792 Squirrel monkey polyomavirus large T gene Proteins 0.000 description 1
- 208000005279 Status Asthmaticus Diseases 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 241000611866 Tyrophagus putrescentiae Species 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 208000037919 acquired disease Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000009285 allergic inflammation Effects 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- PHTAQVMXYWFMHF-QVPNGJTFSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-beta-D-GlcpNAc Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H](O[C@@H](O)[C@H](NC(C)=O)[C@H]2O)CO)O[C@H](CO)[C@H](O)[C@@H]1O PHTAQVMXYWFMHF-QVPNGJTFSA-N 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical class O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940046528 grass pollen Drugs 0.000 description 1
- 239000013574 grass pollen allergen Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- PPZMYIBUHIPZOS-UHFFFAOYSA-N histamine dihydrochloride Chemical compound Cl.Cl.NCCC1=CN=CN1 PPZMYIBUHIPZOS-UHFFFAOYSA-N 0.000 description 1
- 229960000645 histamine hydrochloride Drugs 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000014726 immortalization of host cell Effects 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 238000011330 nucleic acid test Methods 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 238000009117 preventive therapy Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- XQTLDIFVVHJORV-UHFFFAOYSA-N tecnazene Chemical compound [O-][N+](=O)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl XQTLDIFVVHJORV-UHFFFAOYSA-N 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
- C07K14/43531—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from mites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Insects & Arthropods (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200800827 | 2008-03-25 | ||
| ES200800827 | 2008-03-25 | ||
| PCT/IB2009/005114 WO2009118642A2 (en) | 2008-03-25 | 2009-03-24 | Hypoallergenic hybrid proteins of major group 1 and 2 mite allergens for use in the treatment of allergies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015075517A Division JP6068544B2 (ja) | 2008-03-25 | 2015-04-02 | アレルギーの治療に用いるための、主要グループ１ダニアレルゲンおよび主要グループ２ダニアレルゲンの低アレルゲン性ハイブリッドタンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011517407A JP2011517407A (ja) | 2011-06-09 |
| JP2011517407A5 JP2011517407A5 (OSRAM) | 2012-05-17 |
| JP5793073B2 true JP5793073B2 (ja) | 2015-10-14 |
Family
ID=41110539
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011501318A Expired - Fee Related JP5793073B2 (ja) | 2008-03-25 | 2009-03-24 | アレルギーの治療に用いるための、主要グループ１ダニアレルゲンおよび主要グループ２ダニアレルゲンの低アレルゲン性ハイブリッドタンパク質 |
| JP2015075517A Expired - Fee Related JP6068544B2 (ja) | 2008-03-25 | 2015-04-02 | アレルギーの治療に用いるための、主要グループ１ダニアレルゲンおよび主要グループ２ダニアレルゲンの低アレルゲン性ハイブリッドタンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015075517A Expired - Fee Related JP6068544B2 (ja) | 2008-03-25 | 2015-04-02 | アレルギーの治療に用いるための、主要グループ１ダニアレルゲンおよび主要グループ２ダニアレルゲンの低アレルゲン性ハイブリッドタンパク質 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US8951530B2 (OSRAM) |
| EP (3) | EP2436691B1 (OSRAM) |
| JP (2) | JP5793073B2 (OSRAM) |
| CN (2) | CN107118265A (OSRAM) |
| BR (1) | BRPI0908848A2 (OSRAM) |
| CA (1) | CA2718994C (OSRAM) |
| ES (2) | ES2638308T3 (OSRAM) |
| MX (1) | MX2010010353A (OSRAM) |
| WO (1) | WO2009118642A2 (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011260233C1 (en) * | 2010-06-03 | 2015-04-16 | Alk-Abello A/S | Pharmaceutical product comprising mite allergen extract(s) and a method for the manufacture thereof |
| EP2460824A1 (en) | 2010-12-01 | 2012-06-06 | Biomay Ag | Hypoallergenic polypeptides for the treatment of house dust mite allergy |
| CN102676568A (zh) * | 2012-05-08 | 2012-09-19 | 崔玉宝 | 一种生产重组粉尘螨变应原Der f1和Der f2融合蛋白的方法 |
| EP2727934B1 (en) | 2012-09-20 | 2016-06-15 | Universidad de Cartagena | Fusion proteins with representation of different allergens: vaccine proposal for mite allergies |
| CN107001434B (zh) * | 2014-12-02 | 2021-08-24 | 大鹏药品工业株式会社 | 新型粉尘螨蛋白质 |
| NL2014882B1 (en) * | 2015-05-29 | 2017-01-31 | Citeq B V | Allergy-specific immunotherapy compositions for use in the treatment of house-dust mite allergy. |
| EA201890856A1 (ru) * | 2015-09-30 | 2018-10-31 | Бёрингер Ингельхайм Ветмедика Гмбх | Улучшенные транспортные молекулы модулярного антигена и их применение у животных |
| KR101858840B1 (ko) | 2016-01-15 | 2018-05-16 | 단국대학교 천안캠퍼스 산학협력단 | 집먼지진드기 유래 알레르겐에 의한 과민반응 면역조절제 |
| GB201602850D0 (en) * | 2016-02-18 | 2016-04-06 | Bial Ind Farmaceutica S A | Fusion proteins |
| CN108265056B (zh) * | 2016-12-31 | 2019-08-30 | 江苏众红生物工程创药研究院有限公司 | 一种重组户尘螨1类变应原蛋白及其制备方法和应用 |
| CN109852652B (zh) * | 2017-11-30 | 2023-05-02 | 江苏众红生物工程创药研究院有限公司 | 重组尘螨Ⅰ型变应原Der p1和Der f1蛋白的制备与应用 |
| EP3569612A1 (en) | 2018-05-18 | 2019-11-20 | Biomay Ag | Treatment and prevention of house dust mite allergies |
| CN113831400A (zh) * | 2021-07-29 | 2021-12-24 | 沈阳医学院 | 一种尘螨致敏蛋白Der p 1的分离纯化方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0362290A4 (en) * | 1987-06-17 | 1991-09-25 | Princess Margaret Children's Medical Research Foundation (Inc.) | Cloning of mite allergens |
| US5433948A (en) * | 1990-02-13 | 1995-07-18 | Thomas; Wayne R. | Cloning and sequencing of allergens of dermatophagoides (house dust mite) |
| US7288256B1 (en) * | 1991-10-16 | 2007-10-30 | Merck Patent Gmbh | T cell epitopes of the major allergens from dermatophagoides (house dust mite) |
| GB9724531D0 (en) | 1997-11-19 | 1998-01-21 | Smithkline Biolog | Novel compounds |
| EP1221317A1 (en) | 2000-12-28 | 2002-07-10 | SHAN-Beteiligungsgesellschaft m.b.H. | Vaccines containing hybrid polypeptides consisting of at least two different allergenic proteins |
| FR2841906B1 (fr) | 2002-07-05 | 2006-08-18 | Stallergenes Sa | Molecule d'acide nucleique codant une preproproteine d'allergene d'un acarien du genre dermatophagoides ou euroglyphus et son utilisation pour la production dudit allergene dans les plantes |
| ATE307141T1 (de) * | 2003-01-21 | 2005-11-15 | Biomay Prod & Handel | Verfahren zur vorbereitung von hypoallergenen mosaikproteine |
| CN1780852A (zh) * | 2003-04-25 | 2006-05-31 | 诺和酶股份有限公司 | 组1螨多肽变体 |
| ITRM20040103A1 (it) | 2004-02-27 | 2004-05-27 | Consiglio Nazionale Ricerche | Proteine di fusione comprendenti allergeni della famiglia delle ns-ltps, loro usi e composizioni farmaceutiche che le comprendono. |
| AT501101B1 (de) * | 2004-12-02 | 2008-01-15 | Biomay Ag | Protein-allergen-derivat |
| US20070065468A1 (en) * | 2005-08-29 | 2007-03-22 | National University Of Singapore | Chimeric allergens for immunotherapy |
| CN100374152C (zh) * | 2005-12-23 | 2008-03-12 | 中国农业大学 | 一种过敏性反应抑制剂 |
| GB0607377D0 (en) | 2006-04-12 | 2006-05-24 | Glaxosmithkline Biolog Sa | Novel Methods |
| EP1908777B1 (en) * | 2006-10-06 | 2016-02-03 | Stallergenes | Mite fusion proteins |
| EP1908776A1 (en) * | 2006-10-06 | 2008-04-09 | Stallergenes Sa | Mite fusion proteins |
-
2009
- 2009-03-24 EP EP11179765.0A patent/EP2436691B1/en not_active Not-in-force
- 2009-03-24 ES ES11179765.0T patent/ES2638308T3/es active Active
- 2009-03-24 ES ES11179771.8T patent/ES2638271T3/es active Active
- 2009-03-24 EP EP09724998A patent/EP2268662A2/en not_active Ceased
- 2009-03-24 US US12/934,418 patent/US8951530B2/en not_active Expired - Fee Related
- 2009-03-24 CA CA2718994A patent/CA2718994C/en not_active Expired - Fee Related
- 2009-03-24 EP EP11179771.8A patent/EP2436692B1/en not_active Not-in-force
- 2009-03-24 MX MX2010010353A patent/MX2010010353A/es active IP Right Grant
- 2009-03-24 CN CN201610835971.7A patent/CN107118265A/zh active Pending
- 2009-03-24 BR BRPI0908848A patent/BRPI0908848A2/pt not_active IP Right Cessation
- 2009-03-24 CN CN200980110215.6A patent/CN101977929B/zh not_active Expired - Fee Related
- 2009-03-24 JP JP2011501318A patent/JP5793073B2/ja not_active Expired - Fee Related
- 2009-03-24 WO PCT/IB2009/005114 patent/WO2009118642A2/en not_active Ceased
-
2015
- 2015-02-09 US US14/617,136 patent/US20150152148A1/en not_active Abandoned
- 2015-04-02 JP JP2015075517A patent/JP6068544B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2718994A1 (en) | 2009-10-01 |
| WO2009118642A3 (en) | 2009-12-03 |
| EP2436692A2 (en) | 2012-04-04 |
| CN101977929B (zh) | 2016-10-19 |
| EP2436692A3 (en) | 2012-06-27 |
| WO2009118642A2 (en) | 2009-10-01 |
| EP2436691A3 (en) | 2012-06-27 |
| CA2718994C (en) | 2017-06-13 |
| US20150152148A1 (en) | 2015-06-04 |
| EP2436692B1 (en) | 2017-08-02 |
| CN107118265A (zh) | 2017-09-01 |
| ES2638308T3 (es) | 2017-10-19 |
| MX2010010353A (es) | 2010-10-05 |
| JP6068544B2 (ja) | 2017-01-25 |
| JP2011517407A (ja) | 2011-06-09 |
| US8951530B2 (en) | 2015-02-10 |
| EP2436691A2 (en) | 2012-04-04 |
| CN101977929A (zh) | 2011-02-16 |
| JP2015164424A (ja) | 2015-09-17 |
| ES2638271T3 (es) | 2017-10-19 |
| BRPI0908848A2 (pt) | 2015-12-01 |
| EP2268662A2 (en) | 2011-01-05 |
| EP2436691B1 (en) | 2017-08-02 |
| US20110052640A1 (en) | 2011-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6068544B2 (ja) | アレルギーの治療に用いるための、主要グループ１ダニアレルゲンおよび主要グループ２ダニアレルゲンの低アレルゲン性ハイブリッドタンパク質 | |
| Asturias et al. | Engineering of major house dust mite allergens Der p 1 and Der p 2 for allergen‐specific immunotherapy | |
| JP6042600B2 (ja) | 免疫療法と診断を目的としてピキア・パストリスにおいて“天然様”アレルゲンとして発現する組み換えＤｅｒｐ２ | |
| US20080274059A1 (en) | Mite fusion proteins | |
| CN103339143B (zh) | 用于治疗屋尘螨过敏的低过敏原性多肽 | |
| EP1908777B1 (en) | Mite fusion proteins | |
| AU2007246152A1 (en) | Phl p 1 allergen derivative | |
| CA2475073C (en) | Hypoallergenic polypeptides based on fish parvalbumin | |
| JP6148088B2 (ja) | アレルギー治療に用いるカベイラクサ（Ｐａｒｉｅｔａｒｉａｊｕｄａｉｃａ）の脂質輸送タンパク質ファミリーに属する低アレルギー誘導性のキメラタンパク質 | |
| HK1168861B (en) | Hypoallergenic hybrid proteins of major group 1 and 2 mite allergens for use in the treatment of allergies | |
| HK1168860B (en) | Hypoallergenic hybrid proteins of major group 1 and 2 mite allergens for use in the treatment of allergies | |
| HK1168861A (en) | Hypoallergenic hybrid proteins of major group 1 and 2 mite allergens for use in the treatment of allergies | |
| HK1168860A (en) | Hypoallergenic hybrid proteins of major group 1 and 2 mite allergens for use in the treatment of allergies | |
| US9446121B2 (en) | Cloning of honey bee allergen | |
| EP2794644B1 (en) | Hypoallergenic variants of phl p 5, the major allergen from phleum pratense | |
| US20140121356A1 (en) | Hypoallergenic mutant polypeptides based on fish parvalbumin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110824 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120323 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120323 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131203 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140226 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140305 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140327 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140403 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140502 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20141203 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150402 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20150402 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20150424 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150709 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150807 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5793073 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R154 | Certificate of patent or utility model (reissue) |
Free format text: JAPANESE INTERMEDIATE CODE: R154 |
|
| LAPS | Cancellation because of no payment of annual fees |